A Phase Ⅱb Study of XY03-EA Tablets in Acute Ischemic Stroke | MicrobiomeTrials← Back to trialsNCT06755944
A Phase Ⅱb Study of XY03-EA Tablets in Acute Ischemic Stroke
CompletedPHASE2INTERVENTIONAL
Trial Details
Start: 2024-12-15Est. Completion: 2025-06-09
Enrollment target: 360 participants Locations- Shijiazhuang Yiling Pharmaceutical Co., Ltd, Shijiazhuang, Hebei, China
Other microbiome trials you might be interested in
Ischemic Stroke
In 2015, five randomized trials showed efficacy of endovascular thrombectomy over standard medical care in patients with…
Shenyang, ChinaEst. completion Jun 30, 2028
Ischemic StrokeSmall Vessel Cerebrovascular DiseaseCholesterol, LDLSecondary PreventionCardiovascular Diseases
Lipid-lowering therapy constitutes a cornerstone of secondary prevention in ischemic stroke; however, current stroke gui…
Ansan, South KoreaEst. completion Sep 2030
Nonvalvular Atrial Fibrillation
This prospective, open-label, multicenter randomized controlled trial will compare two preprocedural imaging assessment …
Shanghai, ChinaEst. completion Sep 1, 2028